Cardiax Lab

What Cardiax Lab does

Cardiax Lab (Asia) Limited is a Hong Kong-based private healthcare services company founded in 2019 that operates as the sole distributor of the HOTMAN SYSTEM in the territory. The company delivers non-invasive cardiovascular screening using Thoracic Electrical Bioimpedance Cardiac Output (TEBCO) technology originally developed in 1983 for NASA astronaut cardiac monitoring. The HOTMAN SYSTEM collects up to 29 cardiovascular parameters via eight electrode pads placed on the chest and neck, requires no blood draw, perfusion, or radiation, completes a screening in 2–10 minutes, and carries FDA, CE, and TUV certifications. The system also includes drug prescription support functionality for cardiologists managing hypertension.

Cardiax Lab serves three primary consumer segments — athletes and sports enthusiasts, adults aged 18+, and high-stress executives — through three tiered plans priced at HKD 1,200 (Pro-Sports, 9 parameters), HKD 2,000 (Pro-Health, 18 parameters), and HKD 2,800 (Pro-Executive, 24 parameters). The company augments this consumer business with B2B corporate wellness partnerships (EY Hong Kong, RSM Hong Kong), a co-marketing arrangement with the National Federation of Professional Trainers (NFPT), and a PureHeart supplement offering in partnership with Pure Encapsulations. Operations run from a single Hong Kong service centre relocated to Sheung Wan in April 2022, led by Group Chairman Dr. Bo Sramek (also founder of technology partner Sramek BioDynamics Inc.).

The business model is fundamentally a clinical-services distribution play: Cardiax Lab does not own the HOTMAN technology, which is licensed from SDBI, and its value-add is local clinical operations, corporate wellness channel development, and consumer marketing in Hong Kong. The competitive pitch is built on the claim that 50% of heart attack victims present normal blood pressure and 50% present normal ECG readings, positioning hemodynamic bioimpedance analysis as a complementary screening modality. The company has not disclosed revenue, funding rounds, or headcount trends, and operates with a small staff (11–50 employees).

Name

Cardiax Lab

Legal name

Cardiax Lab (Asia) Limited

Website

https://cardiaxlab.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Cardiax Lab is the Hong Kong sole distributor of the FDA/CE/TUV-cleared HOTMAN SYSTEM, a non-invasive cardiovascular screening device based on NASA-derived bioimpedance technology. It serves athletes, adults, executives, and corporate wellness clients through three tiered screening plans plus a PureHeart supplement partnership.

Ownership category

akta.pro rank

Product category

Cardiovascular Diagnostic Services

NAICS

Medical Laboratories (621511)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Diagnostic Centers (Echo/Stress Testing/Holter) (HLAFAKAE)

akta.pro secondary industry

Preventive Cardiology & Lipidology (HLAKABAF)

Keywords

• Cardiovascular screening services
• Non-invasive diagnostics
• Hemodynamic analysis
• Preventive health screening
• Heart health monitoring

Headquarters

HQ city

Sheung Wan

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Cardiovascular Screening Services: One-time screening fees for three tiered cardiovascular assessment plans: Pro-Sports (9 parameters, HKD 1,200), Pro-Health (18 parameters, HKD 2,000), and Pro-Executive (24 parameters, HKD 2,800). Screens are non-invasive, completed in 2-10 minutes using the HOTMAN SYSTEM.
2. Corporate Wellness Programs: B2B partnerships with corporations offering exclusive cardiovascular screening discounts to employees and executives. Notable partnerships with EY Hong Kong and RSM Hong Kong for staff wellness initiatives.
3. Supplement Sales (PureHeart): Partnership with Pure Encapsulations to provide PureHeart cardiovascular supplements as an add-on to screening services. Supplements include EPA/DHA essentials, Vascular Relax, CoQ10, Resveratrol, EndoLOX, Hawthorn Extract, and Magnesium formulations.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cardiax Lab operates cardiovascular screening service centers in Hong Kong using the HOTMAN SYSTEM, a non-invasive AI-guided cardiovascular technology (AIGCT) based on Thoracic Electrical Bioimpedance Cardiac Output (TEBCO) measurement. The service collects up to 29 cardiovascular parameters in 2-10 minutes and delivers immediate PDF reports to customers' mobile devices, available via three tiered plans (Pro-Sports, Pro-Health, Pro-Executive) targeting athletes, general adults, and high-stress executives respectively.

Product overview

Cardiax Lab offers a unified cardiovascular health assessment platform centered on the HOTMAN SYSTEM, a non-invasive AI-guided cardiovascular technology (AIGCT) using Thoracic Electrical Bioimpedance Cardiac Output (TEBCO). The core product provides comprehensive hemodynamic analysis through three screening plan tiers: Pro-Sports (9 parameters), Pro-Health (18 parameters), and Pro-Executive (24 parameters). The HOTMAN SYSTEM is complemented by PureHeart dietary supplements from Pure Encapsulations, enabling a combined screening plus supplementation approach to heart health care. The platform also includes drug prescription support for cardiologists' patients and integrates with Cleveland HeartLab biomarker testing.

Differentiator

Problem solved

Functional benefit

Brands

• PureHeart: Natural supplements for heart health in partnership with Pure Encapsulations, providing EPA/DHA essentials, Vascular Relax, CoQ10, Resveratrol, EndoLOX, Hawthorn Extract, and Magnesium supplements.

Products and services

• HOTMAN Cardiovascular Screening Service A non-invasive cardiovascular screening service using HOTMAN SYSTEM with Thoracic Electrical Bioimpedance Cardiac Output (TEBCO) technology, FDA/CE/TUV approved. Collects up to 29 cardiovascular parameters in 2-10 minutes using 8 electrode pads on chest and neck without blood draw, perfusion, or radiation. Includes drug prescription support for cardiologists and delivers immediate PDF reports to mobile devices. Targeted at adults seeking preventive cardiovascular screening.
• PureHeart Cardiovascular Supplements Natural dietary supplements from Pure Encapsulations offered in partnership with Cardiax Lab to complement HOTMAN cardiovascular screening. Includes EPA/DHA essentials, Vascular Relax, PureHeart K2D, CoQ10, Resveratrol, EndoLOX, Hawthorn Extract, and Magnesium formulations for personalized and proactive heart health support.

Quantifiable outcome

• 50% of heart attack victims presented normal blood pressure level - Cardiax Lab's hemodynamic analysis detects abnormalities not visible in standard blood pressure checks
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Santé de France Limited (SDF)coreStrategic or Co-development Partner · 2 May 2019Partnership established May 2nd, 2019 to increase prevention means and enhance innovative and care character. SDF provides exhaustive health checkups including anti-ageing, hormonal, food intolerance, nutrients and antioxidant profiles. Together with SDBI, they provide preventive solutions for client wellness, enhancing quality of life and longevity.
• Sramek BioDynamics Inc (SDBI)coreStrategic or Co-development Partner · 2 April 2019Partnership established April 2nd, 2019 to set up the first Smart Heart Care center in Hong Kong. Located at 11th floor, 1 Lan Kwai Fong, Central. Cardiax Lab and SDBI are described as 'the heart and soul of this company' sharing the same goal of facilitating access to cardiovascular health. SDBI provides the HOTMAN SYSTEM technology.
• Pure EncapsulationsminorGTM or Marketing PartnerPartnership offering PureHeart cardiovascular supplements combined with HOTMAN screening services. Provides 8 PureHeart supplements including EPA/DHA essentials, Vascular Relax, CoQ10, Resveratrol, EndoLOX, Hawthorn Extract, and Magnesium for heart health support. Screening + Supplements = Success approach.
• Ernst & Young Hong Kong (EY Hong Kong)minorGTM or Marketing PartnerExclusive corporate offer from August 1, 2019 to July 31, 2020 providing EY Hong Kong staff and management teams special discounts on cardiovascular screening plans. Supports corporations in providing care for personnel and ensuring productivity.
• RSM Hong KongminorGTM or Marketing PartnerExclusive corporate offer from April 1, 2020 to March 31, 2021 providing RSM Hong Kong staff and management teams special discounts on cardiovascular screening plans. Targets high-stress audit and finance professionals.
• National Federation of Professional Trainers (NFPT)minorGTM or Marketing PartnerNFPT advises personal trainers to use Cardiax Lab's HOTMAN screening for client health assessment. 24 intensive cardiovascular parameters provide full picture of heart function for training plan guidance and risk identification.

Scale indicators2 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• iRhythm Technologies: iRhythm offers the Zio long-term cardiac monitoring patch and related AI analytics. While continuous rather than spot screening, both companies sell non-invasive, FDA-cleared, AI-supported cardiovascular diagnostic services to clinicians and patients.
• Eko Health: Eko combines digital stethoscopes with AI-driven cardiac and pulmonary analysis, used by clinicians and increasingly in screening workflows. Cardiax Lab and Eko both target AI-augmented cardiovascular screening with FDA-cleared devices aimed at early detection beyond standard vitals.
• AliveCor (KardiaMobile): AliveCor makes FDA-cleared KardiaMobile consumer ECG devices for at-home cardiac screening with instant mobile reporting. Cardiax Lab competes in the same consumer cardiovascular-screening category with a higher-parameter, clinic-based screening experience using HOTMAN.
• HeartFlow: HeartFlow provides non-invasive, AI-guided cardiac diagnostic analysis (FFR-CT) used by cardiologists to detect coronary artery disease. Like Cardiax Lab, HeartFlow delivers advanced non-invasive hemodynamic/cardiovascular insights that go beyond standard ECG to inform treatment decisions.
• Cardio Diagnostics Holdings: Cardio Diagnostics offers AI-driven, non-invasive epigenetic and genetic tests for cardiovascular disease and diabetes risk. It parallels Cardiax Lab's positioning of non-invasive, AI-guided cardiovascular screening marketed directly to consumers and clinicians.

Emerging players

• Cleerly: Cleerly is a growth-stage AI cardiac imaging company focused on coronary CT angiography-based plaque analysis. It competes in the broader 'next-generation cardiovascular screening' category where Cardiax Lab's hemodynamic analysis is positioned.
• TytoCare: TytoCare provides remote telehealth examination devices and platform partnerships with health systems and insurers for at-home screening. It represents an adjacent digital screening model that could overlap with Cardiax Lab's preventive cardiovascular screening focus.

Broad incumbents

• Withings: Withings is a connected-health device maker offering smart blood-pressure monitors, watches with ECG, and body-composition devices. As a broad incumbent in consumer cardiovascular monitoring, it overlaps with Cardiax Lab's preventive screening audience.
• Apple (Health / Apple Watch): Apple Watch's FDA-cleared ECG and irregular-rhythm notifications make Apple a broad incumbent in consumer cardiac screening. Cardiax Lab competes for the same preventive heart-health consumer mindshare with more clinical-grade hemodynamic profiling.

Regional players

• BioIQ: BioIQ is a US-focused corporate wellness and preventive screening platform offering biometric and cardiovascular risk screenings to employers. It mirrors Cardiax Lab's B2B corporate-wellness model in a different geography and is directly comparable as a channel-based preventive cardiac screening partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/cardiaxlab
• LinkedInlinkedin.com/company/cardiax-lab

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiax Lab